Compare Capri Holdings Ltd (CPRI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs TransMedics Group Inc — how do they compare? Capri Holdings Ltd trades at $14.95 (market cap $1.67B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is more actively traded (949,331 versus 3,722,279). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and TransMedics Group Inc for 24 Days on average.
| CPRI | TMDX | |
|---|---|---|
Market Cap | $1.67B | $2.74B |
Volume | 3,722,279 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $150.42 |
52-Week Low | $12.71 | $61.99 |
Typical Hold Time | 41 Days | 24 Days |
Enterprise Value | $2.95B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.68, up 1.66% today, with a bullish technical signal from moving averages. The stock has beaten EPS estimates in recent quarters, but faces fundamental headwinds with revenue declining to $4.44B in 2025 and a net loss of $1.18B. Analyst consensus is a $20.57 price target, with 44% buy ratings. Recent news highlights brand revitalization efforts and second-half growth expectations from management commentary at the Goldman Sachs conference.
The outlook balances low valuation multiples against operational challenges. Investment appeal lies in potential margin improvement and brand turnaround, but risks include sustained revenue weakness, high debt levels, and competitive pressures in the luxury sector. The stock's recovery hinges on execution of the Michael Kors reset and macroeconomic support for consumer discretionary spending.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
